Form 4: Fulgent Genetics CFO Paul Kim's RSU Tax Withholding

Fulgent Genetics CFO Paul Kim reported a routine disposition of 671 common shares to cover tax obligations from vested restricted stock units.

Summary

• Paul Kim, the Chief Financial Officer and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a transaction on November 23, 2025.
• A total of 671 shares of Fulgent Genetics common stock were disposed of.
• This disposition was executed to satisfy tax withholding obligations that arose from the vesting of restricted stock units (RSUs).
• The RSUs in question were originally granted to Mr. Kim on February 23, 2023.
• The shares were valued at $30 per share for the purpose of tax withholding.
• Following this transaction, Paul Kim's direct beneficial ownership of Fulgent Genetics common stock stands at 333,447 shares.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction where shares were withheld to cover tax obligations upon the vesting of restricted stock units. This is an expected part of executive compensation and does not indicate a significant positive or negative shift in company fundamentals or insider sentiment.

Positives

• The vesting of restricted stock units indicates a successful compensation event for the CFO, aligning executive interests with shareholder value over time.

Negatives

• A reduction of 671 common shares from the CFO's direct beneficial ownership occurred, though this was for tax purposes.

Future Outlook

This filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a routine compensation event for an executive and does not provide specific insights into broader industry trends or competitive dynamics within the genetics or diagnostics sector.

Stakeholder Impact

• Shareholders: The transaction results in a minor, routine reduction in direct insider ownership, which is a standard outcome of executive compensation plans and is unlikely to have a material impact on shareholder sentiment or company valuation.

Key Dates

Recommendation

This Form 4 filing details a routine tax-related disposition of shares by the CFO upon the vesting of restricted stock units. Such transactions are standard practice in executive compensation and do not typically signal any change in the company's fundamental outlook or the insider's confidence. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Fulgent Genetics, FLGT, Paul Kim, Form 4, insider transaction, restricted stock units, RSU vesting, tax withholding, executive compensation